Brown Adipose Tissue: A New Potential Target for Glucagon-like Peptide 1 Receptor Agonists in the Treatment of Obesity
Open accessThe DOI matches its Crossref record; 95 of the 95 references it cites were found in a registry or an index.
Abstract
Adipose tissue can be divided into white adipose tissue (WAT), brown adipose tissue (BAT), and beige adipose tissue, according to the differences in morphology. WAT acts as a buffer for increased energy intake and decreased energy expenditure during the development of obesity, resulting in visceral and ectopic WAT accumulation. These WAT depots are strongly associated with chronic systemic inflammation, insulin resistance, and cardiometabolic risk related to obesity. They represent a primary weight loss target in anti-obesity management. Second-generation anti-obesity medications glucagon-like peptide-1 receptor agonists (GLP-1RAs) cause weight loss and improve body composition by reducing visceral and ectopic fat depots of WAT, resulting in improved cardiometabolic health. Recently, the understanding of the physiological significance of BAT beyond its primary function in generating heat through non-shivering thermogenesis has been expanded. This has raised scientific and pharmaceutical interest in the manipulation of BAT to further enhance weight reduction and body weight maintenance. This narrative review focuses on the potential impact of GLP-1 receptor agonism on BAT, particularly in human clinical studies. It provides an overview of the role of BAT in weight management and highlights the need for further research to elucidate the mechanisms by which GLP-1RAs affect energy metabolism and weight loss. Despite encouraging preclinical data, limited clinical evidence supports the notion that GLP-1RAs contribute to BAT activation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Therefore, BAT activation could potentially improve specific metabolic parameters (hyperglycemia, dyslipidemia) in addition to increasing energy expenditure, making it a viable therapeutic target for obesity and other metabolic diseases [95].”
From Adipose Tissue: A Novel Target of the Incretin Axis? A Paradigm Shift in Obesity-Linked Insulin Resistance (2024) · cites this paper as [95]
In the citing paper
“Preclinical research showed that the main mechanism by which GLP-1 causes weight loss is not only by decreasing appetite and hunger but also by increasing energy expenditure, most likely by means of BAT thermogenesis [95].”
From Adipose Tissue: A Novel Target of the Incretin Axis? A Paradigm Shift in Obesity-Linked Insulin Resistance (2024) · cites this paper as [95]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
‘Small Changes' to Diet and Physical Activity Behaviors for Weight Management
Hills, A. P., Byrne, N. M., Lindstrom, R., & Hill, J. O. (2013) · Obesity Facts · doi:10.1159/000345030 · Cited by 9,493
The metabolic phenotype in obesity: Fat mass, body fat distribution, and adipose tissue function
Goossens, G. H. (2017) · Obesity Facts · doi:10.1159/000471488 · Cited by 8,481
Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. Adults
Calle, E. E., Rodriguez, C., Walker-Thurmond, K., & Thun, M. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021423 · Cited by 7,696
Obesity: global epidemiology and pathogenesis
Blüher, M. (2019) · Nature Reviews Endocrinology · doi:10.1038/s41574-019-0176-8 · Cited by 5,126
Flegal, K. M., Kit, B. K., Orpana, H., & Graubard, B. I. (2013) · JAMA · doi:10.1001/jama.2012.113905 · Cited by 3,998 · cited 1×
“The alarming numbers of obesity prevalence are concerning, given that obesity is associated with increased mortality [3,4].”
BackgroundTirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838 · cited 1×
“However, it has been shown that tirzepatide once weekly is effective in providing a substantial and sustained reduction in body weight in obese persons without diabetes [66].”
BackgroundHaslam, D. W., & James, W. P. T. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67483-1 · Cited by 3,757
Cold-Activated Brown Adipose Tissue in Healthy Men
van Marken Lichtenbelt, W. D., Vanhommerig, J. W., Smulders, N. M., Drossaerts, J. M. A. F. L., Kemerink, G. J., Bouvy, N. D., Schrauwen, P., & Teule, G. J. J. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808718 · Cited by 3,452
Functional Brown Adipose Tissue in Healthy Adults
Virtanen, K. A., Lidell, M. E., Orava, J., Heglind, M., Westergren, R., Niemi, T., Taittonen, M., Laine, J., Savisto, N.-J., Enerbäck, S., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808949 · Cited by 3,058 · cited 2×
“Initial studies exploring BAT activity demonstrated that BAT is present in both lean and obe e individuals; however, BAT activity was observed to be reduc d in overw ight or obese men [33,34].”
BackgroundDi Angelantonio, E., Bhupathiraju, S. N., Wormser, D., Gao, P., Kaptoge, S., de Gonzalez, A. B., Cairns, B. J., Huxley, R., Jackson, C. L., Joshy, G., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30175-1 · Cited by 2,821
Cited by
Spotlight on the Mechanism of Action of Semaglutide
Papakonstantinou, I. P., Tsioufis, K. P., & Katsi, V. K. (2024) · Current Issues in Molecular Biology · doi:10.3390/cimb46120872 · Cited by 102
Ngene, N. C., & Moodley, J. (2024) · Best Practice & Research Clinical Obstetrics & Gynaecology · doi:10.1016/j.bpobgyn.2024.102473 · Cited by 71
Amylin: From Mode of Action to Future Clinical Potential in Diabetes and Obesity
Volčanšek, Š., Koceva, A., Jensterle, M., Janež, A., & Muzurović, E. M. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01733-8 · Cited by 35
Self-citationMuzurović, E. M., Katsiki, N., Volčanšek, Š., Plescia, F., Rizzo, M., & Mantzoros, C. S. (2026) · Metabolism · doi:10.1016/j.metabol.2026.156494 · Cited by 25
Quagliariello, V., Canale, M. L., Bisceglia, I., Iovine, M., Giordano, V., Giacobbe, I., Scherillo, M., Gabrielli, D., Maurea, C., Barbato, M., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252011299 · Cited by 23
Interactions between glucagon like peptide 1 (GLP-1) and estrogens regulates lipid metabolism
Model, J. F. A., Normann, R. S., Vogt, É. L., Dentz, M. C. V., de Amaral, M., Xu, R., Bachvaroff, T. R., Spritzer, P. M., Chung, J. S., & Vinagre, A. S. (2024) · Biochemical Pharmacology · doi:10.1016/j.bcp.2024.116623 · Cited by 22
De Fano, M., Malara, M., Vermigli, C., & Murdolo, G. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25168650 · Cited by 17
“Preclinical research showed that the main mechanism by which GLP-1 causes weight loss is not only by decreasing appetite and hunger but also by increasing energy expenditure, most likely by means of BAT thermogenesis [95].”
BackgroundNew Mediators in the Crosstalk between Different Adipose Tissues
Gómez‐Hernández, A., Heras, N. D. L., Gálvez, B. G., Fernández‐Marcelo, T., Fernández‐Millán, E., & Escribano, Ó. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25094659 · Cited by 14
GLP-1 and Its Role in Glycogen Production: A Narrative Review
Lotosky, J., Jean, X., Altankhuyag, A., Khan, S. R., Bernotas, A., Sharafshah, A., Blum, K., Posner, A. R., & Thanos, P. K. (2025) · Biomedicines · doi:10.3390/biomedicines13071610 · Cited by 17
Glucagon‐Like Peptide‐1 Links Ingestion, Homeostasis, and the Heart
Krieger, J., Daniels, D., Lee, S. J., Mastitskaya, S., & Langhans, W. (2024) · Comprehensive physiology · doi:10.1002/cph4.7 · Cited by 15
Do anti-obesity medical treatments have a direct effect on adipose tissue?
Vergès, B. L. (2024) · Annales d Endocrinologie · doi:10.1016/j.ando.2024.05.021 · Cited by 10
Subcutaneous adipose tissue and skeletal muscle mitochondria following weight loss
van der Kolk, B. W., Pirinen, E., Nicoll, R., Pietiläinen, K. H., & Heinonen, S. (2024) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2024.08.002 · Cited by 10
Ábel, T., & Csajbókné, É. C. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27031186 · Cited by 12
MRI Methods to Visualize and Quantify Adipose Tissue in Health and Disease
Nikiforaki, K., & Marias, K. (2023) · Biomedicines · doi:10.3390/biomedicines11123179 · Cited by 14
Brown Adipose Tissue Mimicking Head and Neck Cancer on PET Scan in a Patient on GLP ‐1 Drug
Harrison, D. B., Phillips, A. L., Tansey, J. B., Clarke, T. J., Wood, C. B., Nedzi, L. A., Schwartz, D. L., Makowski, L., Hayes, D. N., Newman, G., et al. (2024) · The Laryngoscope · doi:10.1002/lary.31815 · Cited by 6
Wang, Z., Xu, Q., Hou, L., He, Z., Christian, M., & Dai, X. (2025) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2025.2500675 · Cited by 15
Simka-Lampa, K. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27020754 · Cited by 4
Zhang, M., Wang, H., Li, X., Shu, S., Piao, J., Yue, X., Zhao, S., Li, M., Jin, X., Nan, Y., et al. (2025) · The FASEB Journal · doi:10.1096/fj.202502147r · Cited by 6
Incretins and Development of Incretin‐based Therapeutics
Zheng, N., Su, X., Zhang, S., & Shen, W. (2025) · Wiley eBooks · doi:10.1002/9781119824701.ch09 · Cited by 6
Guo, Z., Deng, S., Li, L., & Liu, M. (2025) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2025.1623148 · Cited by 5
Energy balance and obesity: the emerging role of glucagon like peptide-1 receptor agonists
Beauregard, N., McInnis, K., Goldfield, G. S., & Doucet, É. (2024) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/mco.0000000000001064 · Cited by 11
Cannabis improves metabolic dysfunction and macrophage signatures in obese mice
VanderVeen, B. N., Cardaci, T. D., Unger, C. A., NeSmith, M. M., Freeman, J. C., Bastian, A. V., Roark, K. L., Upadhyay, M., Levy, A. G., Bullard, B. M., et al. (2025) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00503.2025 · Cited by 3
Effects of GLP-1 receptor agonists and dual incretin agonists on adipocyte type and size
Turashvili, N. (2025) · Exploration of Endocrine and Metabolic Diseases · doi:10.37349/eemd.2025.101452 · Cited by 2
Wang, X., Lu, G., Zhou, Y., & Zhao, G. (2026) · Journal of Endocrinological Investigation · doi:10.1007/s40618-026-02891-7 · Cited by 4
Braha, A., Timar, B., Sturza, A., & Timar, R. Z. (2026) · Medicina · doi:10.3390/medicina62081509 · Cited by 2
Metabolic signals in sleep regulation: the role of brown adipose tissue
Szentirmai, É., & Kapás, L. (2025) · Neurobiology of Sleep and Circadian Rhythms · doi:10.1016/j.nbscr.2025.100122 · Cited by 3
Theodorakis, N., Kreouzi, M., & Nikolaou, M. (2025) · Heart Failure Reviews · doi:10.1007/s10741-025-10506-1 · Cited by 3
Toxicity of Semaglutide upon sub chronic administration in Rabbits
Vishwanath, C., Krishnachari, K., Adiga, G. P., Madhavdeshmukh, M., Das, A., Jamal, Z. A., Bhoite, P. Y., Ponnusamy, K., Krishnappa, M., Ahuja, V., et al. (2025) · Toxicological Research · doi:10.1007/s43188-025-00308-w · Cited by 2
Peptide drugs for obesity and type 2 diabetes mellitus: an overview of clinical trials
Barzgar, H., Darmadi, D., Nafisa, J., Narkulov, S., & Sviridova, M. B. (2025) · Clinica Chimica Acta · doi:10.1016/j.cca.2025.120772 · Cited by 2
Correra, A., Mauriello, A., Cetoretta, V., Maratea, A. C., Riegler, L., Sarno, I. D., Giallauria, F., Guerra, F., Russo, V., & D’Andrea, A. (2026) · Pharmaceuticals · doi:10.3390/ph19020297 · Cited by 3
Elsherbini, A. M., Mohamed, S. A., Zayed, A. M., Mouhamed, W. A., & Sabra, S. A. (2026) · OpenNano · doi:10.1016/j.onano.2026.100290 · Cited by 3
Ma, W., Wang, C., Jiang, X., Zeng, Y., Liao, Y., Yi, B., & Feng, S. (2026) · European journal of medical research · doi:10.1186/s40001-026-03860-9
Zhang, R., Peng, G., Pan, X., & Tong, N. (2026) · Scientific Reports · doi:10.1038/s41598-026-45462-9
Effects of once-weekly semaglutide on regional body composition in overweight or obese adults
Ma, Y., Tang, B., Zeng, Y., Zhan, Y., Cong, L., & Hu, F. (2026) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2025.212 · Cited by 1
Ortega, M. P. C., Peña-Peña, M., Carbó, R., Medina-Urrutia, A. X., Osorio‐Alonso, H., Jiang, B., Almanza-Pérez, J. C., Blancas‐Flores, G., Villafaña, S., Romero‐Nava, R., et al. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27156693
Strosahl, J. N., Ziegler, T. R., & Singh, R. H. (2026) · Nutrients · doi:10.3390/nu18162722
GLP‐1 Receptor Agonists and Cancer Risk in Obesity Treatment
Hofseth, L. J., Murphy, E. A., Playdon, M. C., Makowski, L., Ibele, A. R., Fairman, C. M., & Hébert, J. R. (2026) · Obesity Reviews · doi:10.1111/obr.70247
Smarkusz-Zarzecka, J., Radziszewska, M., Gofron, K. K., & Ostrowska, L. (2026) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-026-10098-7 · Cited by 1
Mirmiranpour, H., & BARBER, T. M. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1949288
Metadata
- Authors
- Hropot, T., Herman, R., Janez, A., Lezaic, L., & Jensterle, M.
- Affiliations
- Ljubljana University Medical Centre (SI)
- University of Ljubljana (SI)
- Department for Endocrinology, Diabetes and Metabolic Diseases, University Medical Centre Ljubljana, 1000 Ljubljana, Slovenia
- Department of Internal Medicine, Faculty of Medicine, University of Ljubljana, 1000 Ljubljana, Slovenia
- Corresponding author
- Jensterle, Mojca
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2023-05-11
- Volume
- 24
- Issue
- 10
- Pages
- 8592
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC10218520
- OpenAlex
- W4378515206
- Cited by
- 39
- References
- 94
- Citations by year
- 2026: 15 · 2025: 12 · 2024: 11 · 2023: 1
- FWCI
- 1.39
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Slovenian Research Agency (ARRS) (P3-0298)
- Topics
- Health Sciences › Medicine › Physiology (medical) › Adipose Tissue and Metabolism
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Keywords
- brown adipose tissue, GLP-1 receptor agonists, obesity treatment, weight loss, beige adipose tissue, white adipose tissue, non-shivering thermogenesis, energy metabolism, insulin resistance, cardiometabolic risk, visceral fat, anti-obesity drugs
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Glucagon-Like Peptide-1 Receptor Agonists, Animals, Adipose Tissue, Brown, Cardiovascular Diseases, Energy Metabolism, Humans, Obesity, Weight Loss, Thermogenesis, Glucagon-Like Peptide 1, Adipose Tissue, White
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.